Status:
RECRUITING
Detecting Changes in Arterial Blood Volume and Cardiac Efficiency
Lead Sponsor:
HemoCept Inc.
Conditions:
Aortic Valve Stenosis
Eligibility:
All Genders
18-80 years
Brief Summary
The objective of this Pilot Study is to demonstrate the efficacy of the Hemocept device in detecting changes in arterial blood volume and cardiac efficiency.
Eligibility Criteria
Inclusion
- Subjects or representatives must have voluntarily signed the informed consent form before any study related procedures.
- Subjects can be any gender but must be between (and including) the ages of 18 and 80.
- Subject ls being treated by the participating healthcare facility .
- ., Subject requires a trans-aortic valve replacement.
- Subject is able and willing to provide informed consent and HIPM authorization.
- Subject is able and willing to meet all study requirements.
Exclusion
- Subject is pregnant, breast-feeding, or intends to become pregnant during the course of the study.
- Subject has a personal medical history that includes:
- Long O-T syndrome
- Cardiac channelopathies
- Seizures
Key Trial Info
Start Date :
April 29 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT07205341
Start Date
April 29 2025
End Date
March 1 2026
Last Update
December 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Boulder Heart
Boulder, Colorado, United States, 80303